Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study

Starting soon

Conditions studied: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

In brief

This is a cross-sectional study that will be conducted across Japan using an online patient-reported outcome questionnaire. This study tries to find out the attitudes toward and experiences of the emotional and/or social impact of side effects associated with antifibrotic (AF) treatment among Japanese patients with Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF), and how are these attitudes associated with patients' individual characteristics.

Key facts

Study ID

NCT07743996

Run by

Boehringer Ingelheim

People needed

100

Starts

2026-08-01

Expected to finish

2026-09-30

Last updated by the study team

2026-08-04

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with IPF aged 40 years or older who received nintedanib or pirfenidone within the previous 4 weeks, or patients with PPF aged 18 years or older who received nintedanib within the previous 4 weeks
• Patients capable of responding to a self-administered questionnaire

You may not qualify if…

• Patients treated with nerandomilast (including clinical trials)
• Patients with PPF treated with pirfenidone
• Patients currently hospitalized
• Patients with malignant tumors

Where it is running

• Nippon Boehringer Ingelheim Co., Ltd. — Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.